EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy

Food allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes....

Descripción completa

Detalles Bibliográficos
Autores: Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, Beyer K, Bindslev-Jensen C, Burks W, Ebisawa M, Eigenmann P, Knol E, Nadeau KC, Poulsen LK, van Ree R, Santos AF, du Toit G, Dhami S, Nurmatov U, Boloh Y, Makela M, O'Mahony L, Papadopoulos N, Sackesen C, Agache I, Angier E, Halken S, Jutel M, Lau S, Pfaar O, Ryan D, Sturm G, Varga EM, van Wijk RG, Sheikh A, Muraro A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p22783
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22783
Access Level:acceso abierto
Palabra clave:adolescent
adult
allergen immunotherapy
allergy
food
pediatric
id ES_0629a0a37aad8ae91fc5f17ced1abdcd
oai_identifier_str oai:fsjd.fundanetsuite.com:p22783
network_acronym_str ES
network_name_str España
repository_id_str
spelling EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergyPajno GBFernandez-Rivas MArasi SRoberts GAkdis CAAlvaro-Lozano MBeyer KBindslev-Jensen CBurks WEbisawa MEigenmann PKnol ENadeau KCPoulsen LKvan Ree RSantos AFdu Toit GDhami SNurmatov UBoloh YMakela MO'Mahony LPapadopoulos NSackesen CAgache IAngier EHalken SJutel MLau SPfaar ORyan DSturm GVarga EMvan Wijk RGSheikh AMuraro Aadolescentadultallergen immunotherapyallergyfoodpediatricFood allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral FA-AIT has most frequently been assessed: here, the allergen is either immediately swallowed (OIT) or held under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow's milk, hen's egg, and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. Adverse events during FA-AIT have been frequently reported, but few subjects discontinue FA-AIT as a result of these. Taking into account the current evidence, FA-AIT should only be performed in research centers or in clinical centers with an extensive experience in FA-AIT. Patients and their families should be provided with information about the use of FA-AIT for IgE-mediated food allergy to allow them to make an informed decision about the therapy.WILEY2018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22783ALLERGYISSN: 01054538ISSNe: 13989995reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p227832026-05-27T12:37:41Z
dc.title.none.fl_str_mv EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
title EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
spellingShingle EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
Pajno GB
adolescent
adult
allergen immunotherapy
allergy
food
pediatric
title_short EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
title_full EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
title_fullStr EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
title_full_unstemmed EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
title_sort EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
dc.creator.none.fl_str_mv Pajno GB
Fernandez-Rivas M
Arasi S
Roberts G
Akdis CA
Alvaro-Lozano M
Beyer K
Bindslev-Jensen C
Burks W
Ebisawa M
Eigenmann P
Knol E
Nadeau KC
Poulsen LK
van Ree R
Santos AF
du Toit G
Dhami S
Nurmatov U
Boloh Y
Makela M
O'Mahony L
Papadopoulos N
Sackesen C
Agache I
Angier E
Halken S
Jutel M
Lau S
Pfaar O
Ryan D
Sturm G
Varga EM
van Wijk RG
Sheikh A
Muraro A
author Pajno GB
author_facet Pajno GB
Fernandez-Rivas M
Arasi S
Roberts G
Akdis CA
Alvaro-Lozano M
Beyer K
Bindslev-Jensen C
Burks W
Ebisawa M
Eigenmann P
Knol E
Nadeau KC
Poulsen LK
van Ree R
Santos AF
du Toit G
Dhami S
Nurmatov U
Boloh Y
Makela M
O'Mahony L
Papadopoulos N
Sackesen C
Agache I
Angier E
Halken S
Jutel M
Lau S
Pfaar O
Ryan D
Sturm G
Varga EM
van Wijk RG
Sheikh A
Muraro A
author_role author
author2 Fernandez-Rivas M
Arasi S
Roberts G
Akdis CA
Alvaro-Lozano M
Beyer K
Bindslev-Jensen C
Burks W
Ebisawa M
Eigenmann P
Knol E
Nadeau KC
Poulsen LK
van Ree R
Santos AF
du Toit G
Dhami S
Nurmatov U
Boloh Y
Makela M
O'Mahony L
Papadopoulos N
Sackesen C
Agache I
Angier E
Halken S
Jutel M
Lau S
Pfaar O
Ryan D
Sturm G
Varga EM
van Wijk RG
Sheikh A
Muraro A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv adolescent
adult
allergen immunotherapy
allergy
food
pediatric
topic adolescent
adult
allergen immunotherapy
allergy
food
pediatric
description Food allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral FA-AIT has most frequently been assessed: here, the allergen is either immediately swallowed (OIT) or held under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow's milk, hen's egg, and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. Adverse events during FA-AIT have been frequently reported, but few subjects discontinue FA-AIT as a result of these. Taking into account the current evidence, FA-AIT should only be performed in research centers or in clinical centers with an extensive experience in FA-AIT. Patients and their families should be provided with information about the use of FA-AIT for IgE-mediated food allergy to allow them to make an informed decision about the therapy.
publishDate 2018
dc.date.none.fl_str_mv 2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22783
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22783
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv ALLERGY
ISSN: 01054538
ISSNe: 13989995
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402899666173952
score 15,812429

Similares en LA Referencia